Japan Multinational Trial Organization   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3
Founded: Nagoya Japan (1992)

Organization Overview

First Clinical Trial
2001
NCT00079287
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 3)

Colorectal Neoplasms (Phase 3)

Lung Neoplasms (Phase 3)

Small Cell Lung Carcinoma (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 10